Uncontrolled hypertension or metabolic disease
Neurodegenerative disorders (i.e. Parkinson disease. LBD, or FTD).
Dementia or Mild cognitive impairment at baseline
Long life major depression. Baseline scores =16 on the 17-item Hamilton Depression Scale at baseline.
Long-life DSM-IV axis 1 disorders.
Mental retardation.
Substance abuse.
Concurrent medication limiting validity of neuropsychological tests or imaging.
Anti-depressants with anti-cholinergic properties
Monoamine oxidase inhibitors (MAOi)
Regular use of narcotic analgesics (>2 doses per week).
Use of neuroleptics
Use of anti-dementia medications (Aricept, Exelon, Razadyne) and memantine (Namenda)) or anti-Parkinsonian medications (Sinemet, amantadine, bromocriptine, pergolide, selegeline).
Individuals taking over the counter memory enhancing or protecting medications (e.g. ginkgo biloba, vitamins) are not excluded.
Implanted medical devices that are incompatible with MRI imaging.
Radiation exposures exceeding annual Rad Worker limits.
Heart failure stage D as defined by American Heart Association (7).
Chronic kidney disease in stages = 4, as defined per National Kidney Foundation (8).
Brain tumor and other neoplastic disorders outside the brain where disease itself or its treatment (radiation, chemotherapy) is likely to affect brain structure or function.
Stroke when meeting criteria for total anterior, partial anterior or posterior circulation infarct according to the Oxford Community Stroke Project classification. Patients with clinically silent of lacunar strokes and transient ischemic attacks will not be excluded.
Significant head trauma.
Hydrocephalus.
Hostility or refusal to cooperate

NCT03663387_exc_T1
Condition
hypertension
NCT03663387_exc_T2
Condition
metabolic disease
NCT03663387_exc_T3
Qualifier
Uncontrolled
NCT03663387_exc_T4
Scope
hypertension or metabolic disease
NCT03663387_exc_T5
Condition
Neurodegenerative disorders
NCT03663387_exc_T6
Condition
Parkinson disease
NCT03663387_exc_T7
Condition
LBD
NCT03663387_exc_T8
Condition
FTD
NCT03663387_exc_T9
Scope
Parkinson disease. LBD, or FTD
NCT03663387_exc_T10
Condition
Dementia
NCT03663387_exc_T11
Condition
Mild cognitive impairment
NCT03663387_exc_T12
Measurement
cognitive impairment
NCT03663387_exc_T13
Value
Mild
NCT03663387_exc_T14
Temporal
at baseline
NCT03663387_exc_T15
Scope
Dementia or Mild cognitive impairment
NCT03663387_exc_T16
Condition
Long life major depression
NCT03663387_exc_T17
Measurement
Baseline scores
NCT03663387_exc_T18
Value
=16
NCT03663387_exc_T19
Measurement
17-item Hamilton Depression Scale
NCT03663387_exc_T20
Temporal
at baseline
NCT03663387_exc_T21
Reference_point
baseline
NCT03663387_exc_T22
Condition
Long-life DSM-IV axis 1 disorders
NCT03663387_exc_T23
Condition
Mental retardation
NCT03663387_exc_T24
Condition
Substance abuse
NCT03663387_exc_T25
Temporal
Concurrent
NCT03663387_exc_T26
Drug
medication
NCT03663387_exc_T27
Qualifier
limiting validity of neuropsychological tests
NCT03663387_exc_T28
Qualifier
g validity of neurop .
Anti-
NCT03663387_exc_T29
Scope
limiting validity of neuropsychological tests or imaging
NCT03663387_exc_T30
Drug
Anti-depressants
NCT03663387_exc_T31
Qualifier
anti-cholinergic properties
NCT03663387_exc_T32
Drug
anti-cholinergic
NCT03663387_exc_T33
Drug
Monoamine oxidase inhibitors (MAOi)
NCT03663387_exc_T34
Drug
narcotic analgesics
NCT03663387_exc_T35
Multiplier
>2 doses per week
NCT03663387_exc_T36
Multiplier
Regular use
NCT03663387_exc_T37
Drug
neuroleptics
NCT03663387_exc_T38
Drug
anti-dementia medications
NCT03663387_exc_T39
Drug
Aricept
NCT03663387_exc_T40
Drug
Exelon
NCT03663387_exc_T41
Drug
Razadyne
NCT03663387_exc_T42
Scope
Aricept, Exelon, Razadyne
NCT03663387_exc_T43
Drug
memantine
NCT03663387_exc_T44
Drug
Namenda
NCT03663387_exc_T45
Drug
anti-Parkinsonian medications
NCT03663387_exc_T46
Drug
Sinemet
NCT03663387_exc_T47
Drug
amantadine
NCT03663387_exc_T48
Drug
bromocriptine
NCT03663387_exc_T49
Drug
pergolide
NCT03663387_exc_T50
Drug
selegeline
NCT03663387_exc_T51
Scope
Sinemet, amantadine, bromocriptine, pergolide, selegeline
NCT03663387_exc_T52
Drug
ter memory enhancing or protectin e.g. ginkgo
NCT03663387_exc_T53
Drug
ter memory enhancing or dications (e.g. ginkgo
NCT03663387_exc_T54
Drug
ginkgo biloba
NCT03663387_exc_T55
Drug
vitamins
NCT03663387_exc_T56
Scope
ginkgo biloba, vitamins
NCT03663387_exc_T57
Scope
over the counter memory enhancing or protecting medications
NCT03663387_exc_T59
Device
medical devices
NCT03663387_exc_T60
Procedure
MRI imaging
NCT03663387_exc_T61
Qualifier
incompatible with MRI imaging
NCT03663387_exc_T62
Measurement
Radiation exposures
NCT03663387_exc_T63
Value
exceeding annual Rad Worker limits
NCT03663387_exc_T64
Condition
Heart failure
NCT03663387_exc_T65
Measurement
stage
NCT03663387_exc_T66
Value
D
NCT03663387_exc_T68
Qualifier
American Heart Association
NCT03663387_exc_T69
Condition
Chronic kidney disease
NCT03663387_exc_T70
Measurement
stages
NCT03663387_exc_T71
Value
= 4
NCT03663387_exc_T72
Qualifier
National Kidney Foundation
NCT03663387_exc_T67
Condition
Brain tumor
NCT03663387_exc_T73
Condition
neoplastic disorders
NCT03663387_exc_T74
Qualifier
outside the brain
NCT03663387_exc_T75
Qualifier
likely to affect brain structure
NCT03663387_exc_T76
Qualifier
rain structure or func hen meet
NCT03663387_exc_T77
Procedure
radiation
NCT03663387_exc_T78
Procedure
chemotherapy
NCT03663387_exc_T79
Scope
Brain tumor and other neoplastic disorders outside the brain where disease itself or its treatment (radiation, chemotherapy)
NCT03663387_exc_T80
Scope
ikely to affect brain structure or function
NCT03663387_exc_T81
Condition
Stroke
NCT03663387_exc_T82
Condition
circulation infarct
NCT03663387_exc_T83
Qualifier
posterior
NCT03663387_exc_T84
Qualifier
total anterior
NCT03663387_exc_T85
Qualifier
partial anterior
NCT03663387_exc_T86
Scope
total anterior, partial anterior or posterior
NCT03663387_exc_T87
Measurement
Oxford Community Stroke Project classification
NCT03663387_exc_T89
Qualifier
Significant
NCT03663387_exc_T90
Condition
head trauma
NCT03663387_exc_T91
Condition
Hydrocephalus
NCT03663387_exc_T92
Observation
refusal to cooperate
NCT03663387_exc_T93
Observation
Hostility